Sign in
CompletedNo phase

Intravitreal Bevacizumab Versus Posterior Sub-Tenon Triamcinolone Acetonide for Treating Diabetic Macular Edema

Key facts

Who runs it
Muhammad Aamir Latif
Where
Pakistan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
46 people enrolled
Started
1 Oct 2025
Ended
30 Jun 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Bevacizumab Intravitreal Injection
  • Triamcinolone Acetonide Injection
Record updated
12 November 2026

Who can take part

Age
25 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Patients of either gender
  • Aged 25-75 years
  • With DME for more than three months
  • CMT >300 μm

Who cannot take part

  • Patients with a previous history of intravitreal bevacizumab
  • Previous intraocular surgery
  • Previous focal/grid laser treatment
  • Ocular trauma
  • Media opacities (dense cataract or corneal opacity)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Local data comparing the effects of intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide on central macular thickness (CMT) in patients with diabetic macular edema (DME) are scarce. Therefore, the present study was undertaken to evaluate and compare the short-term anatomical outcomes of these two treatments in terms of CMT reduction.

The 2 groups in the trial

  • Bevacizumab-GroupTreatment being tested

    Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.

    Treatment: Bevacizumab Intravitreal Injection

  • Triamcinolone acetonide-GroupTreatment being tested

    Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.

    Treatment: Triamcinolone Acetonide Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema
Record updated
12 November 2026